Boston Scientific Marks Progress On Regulatory, Restructuring Efforts
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific expects FDA to lift restrictions stemming from a two-year-old corporate warning letter by mid-year following the agency's recent commencement of manufacturing site inspections, the company says